Regenerative BioScience, Inc., a Wholly Owned Subsidiary of Caribbean International Holdings (CIHN), Announces Its Plans to E...
May 07 2014 - 5:00PM
Caribbean International Holdings (Pink
Sheets:CIHN) through its subsidiary, Regenerative BioScience, Inc.,
("RBS") today announced that a noted member of its Advisory Board
and a scientific advisor for Regenerative Biosciences, Rafael
Gonzalez, Ph.D. has been conducting negotiations on the Company's
behalf with a California based "stem cell banking" company.
Dr. Gonzalez stated: "We are now in collaborative talks with a
new California based stem cell banking company with years of
research in the stem cell field called TheBioBox. They will store
adult stem cells (bone marrow and fat) for Regenerative Biosciences
patients for future use. I am particularly excited about arranging
a "marriage" between RBS and this new company as it will allow us
to offer "cutting edge services" to our patients. This is important
because stem cells age just as we do and the younger you are when
you harvest and store them, the greater the possibilities.
Researchers have found that by replacing aging cells with younger
ones, we may be able to stop or slow down the progression of age
related diseases."
Dr. Gonzalez went on to say: "Storing your stem cells for future
use is of paramount importance. It may possibly buy you time and an
improved quality of life when needed."
Steven Swank, Chairman and CEO of Caribbean International
Holdings, stated, "When we added Dr. Gonzales to our Advisory Board
it was in part because of his connection in the overall field of
stem cell research. His position as a Director at a new
cryopreservation company, TheBioBox, which stores adult cells for
future use, gave us an advantage to enter into a relationship with
them."
Dr. Gonzalez is responsible for the development of clinical stem
cell applications for several disease/trauma states for DaVinci
Biosciences, LLC. Dr. Gonzalez is responsible for the design and
execution of all pre-clinical and clinical experiments involving
adult (bone marrow, menstrual blood, adipose) and pre-natal stem
cells (neural, bone marrow, liver, gonadal). He also manages
research and development personnel in accordance with company
development milestones. Dr. Gonzalez also leads the biological tool
based affiliate company DV Biologics which markets cells and cell
based products for research and drug screening. He is a Director of
TheBioBox.
The Company had previously announced that on May 15th to the
17th, Dr. Rafael Gonzalez, will be a guest speaker at the 22nd
Annual World Congress on ANTI-AGING, REGENERATIVE & AESTHETIC
MEDICINE, in Orlando, Florida.
About The Company:
Caribbean International Holdings, Inc. is a holding company for
Regenerative Bio Science, Inc. ("RBSI"). The Company subsidiary
RBSI is focused on helping individuals protect and ensure their
future quality of life through Adult Stem Cell Incubation and the
practice of regenerative medicine in the United States and the
Dominican Republic. RBSI's mission is not only to allow patients to
store their Stem Cells for future use, but also perform patient
funded stem cell therapies for degenerative diseases such as MS,
Arthritis, Degenerative Heart Diseases, Diabetes and a host of
experimental therapies in the brain trauma disease sector including
CTE. The goal is to become a global leader in establishing
protocols that can be patented and utilized to heal patients around
the world.
Adult stem cells work as the repairmen of the body by
replenishing and regenerating damaged tissues and cells. Certain
conditions have shown marked improvement when treated with adult
stem cells taken from the patient's own body. Regenerative
BioScience is a revolution in healthcare using a patient's own
adult stem cells.
For more information go to:
http://www.regenerativebioscience.com/index.html
About: Rafael Gonzalez, Ph.D.
Dr. Gonzalez has expertise in degenerative disorders involving
the spinal cord and has extensive experience in stem cell culture
and biology from human embryonic, pre-natal and adult sources.
Prior to joining DaVinci Biosciences, Dr. Gonzalez served as a
Research Scientist at PrimeGen Biotech where he was responsible for
the design and execution of experiments involving adult (bone
marrow, menstrual blood, adipose) and pre-natal stem cells (neural,
bone marrow, liver, gonadal) for potential clinical application.
Dr. Gonzalez was also responsible for developing PrimeGen's
pre-clinical stem cell/spinal cord injury model.
Dr. Gonzalez developed his thesis at the Reeve-Irvine Research
Center, University of California, Irvine, under the advisory of Dr.
Hans Keirstead, entitled: "The Role of the Chemokine CXCL10 in
Secondary Degeneration Following Spinal Cord Injury." Pre-clinical
studies conducted during this time lead by Dr. Gonzalez were aimed
at reducing secondary degenerative effects. The studies conducted
by Dr. Gonzalez and Dr. Keirstead precipitated the start-up of
Ability Biomedical, a company that developed anti-IP10 antibody, an
antibody which can be used to treat several degenerative disorders
such as multiple sclerosis, rheumatoid arthritis, and SCI. Ability
Biomedical was purchased by Medarex in 2007 which was purchased by
Bristol-Myers Squibb that sponsors a phase II clinical trial using
anti-IP10 antibody (MDX-1100). He also was involved with
preclinical studies in the development of the use of human
embryonic stem cells into spinal cord injury.
Dr. Gonzalez has several scientific publications in the field of
stem cells, spinal cord injury and the immune system.
Dr. Gonzalez received his BS in Biological Science and his Ph.D.
in Anatomy and Neurobiology from the University of California,
Irvine, CA.
Forward-Looking Statements
Except for statements of historical fact, the matters discussed
in this press release are forward looking and made pursuant to the
Safe Harbor provisions of the Private Securities Litigation Reform
Act of 1995. "Forward-looking statements" describe future
expectations, plans, results, or strategies and are generally
preceded by words such as "future," "plan" or "planned," "expects,"
or "projected." These forward-looking statements reflect numerous
assumptions and involve a variety of risks and uncertainties, many
of which are beyond the company's control that may cause actual
results to differ materially from stated expectations. These risk
factors include, among others, limited operating history,
difficulty in developing, exploiting and protecting proprietary
technologies, intense competition and additional risks factors as
discussed in reports filed by the company with the Securities and
Exchange Commission, which are available on at
http://www.sec.gov.
CONTACT: Investor Contact:
BioScience
(941) 924-9400
BioStem Technologies (PK) (USOTC:BSEM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioStem Technologies (PK) (USOTC:BSEM)
Historical Stock Chart
From Apr 2023 to Apr 2024